Drug Trial Radar · NCT06630299
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1
Last checked: Nov 19, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Oct 8, 2024
Primary completion
Apr 23, 2026
Study completion Aug 2030
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Oct 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to learn more about the safety and efficacy of switching to a once weekly tablet of islatravir/lenacapavir (ISL/LEN) regimen versus continuing standard of care treatment in people with human immunodeficiency virus (PWH) who are virologically suppressed (HIV-1 RNA levels \< 50 copies/mL) on a stable standard of care regimen for ≥ 6 months prior to screening. The standard of care includes 2 or 3 medicines, antiretroviral agents (ARVs). The primary objective of the study is to evaluate the efficacy of switching to oral weekly ISL/LEN tablet regimen versus continuing standard of care in virologically suppressed PWH at Week 48.
Conditions
- HIV-1-Infection
Interventions
ISL/LENDrug
Tablet administered orally
Antiretroviral CombinationsDrug
2 or 3 antiretrovirals (ARVs) administered as defined by the investigator, according to the prescribing information.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 as Determined by the United States (US) Food and Drug Administration (FDA)-defined Snapshot AlgorithmTime frame: Week 48
Locations
100 sites in 14 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham(UAB) 1917 Research Clinic
Birmingham, Alabama
Pueblo Family Physicians
Phoenix, Arizona
Vv-Tmf-5366229
Los Angeles, California
Ruane Clinical Research Group
Los Angeles, California
BIOS Clinical Research
Palm Springs, California
Vivent Health
Denver, Colorado
University of Colorado Clinical and Translational Research Center
Denver, Colorado
Yale University; School of Medicine; AIDS Program
New Haven, Connecticut
Georgetown University Medical Center
Washington D.C., District of Columbia
Aids Healthcare Foundation - Northpoint
Fort Lauderdale, Florida
Midway Immunology and Research Center
Ft. Pierce, Florida
CAN Community Health
Miami Gardens, Florida
Orlando Immunology Center
Orlando, Florida
AHF Pensacola
Pensacola, Florida
CAN Community Health
Sarasota, Florida
BayCare Health System, Inc./St. Joseph's Hospital
Tampa, Florida
Triple O Research Institute, P.A.
West Palm Beach, Florida
Metro Infectious Disease Consultants, P.L.L.C.
Decatur, Georgia
Mercer University, Department of Internal Medicine
Macon, Georgia
Chatham County Health Department
Savannah, Georgia
Howard Brown Health Center
Chicago, Illinois
Indiana CTSI Clinical Research Center
Indianapolis, Indiana
Brigham and Womens's Hospital
Boston, Massachusetts
Boston Medical Center
Boston, Massachusetts
Community Research Initiative of New England d/b/a Community Resource Initiative (CRI)
Boston, Massachusetts
Be Well Medical Center
Berkley, Michigan
Henry Ford Health
Detroit, Michigan
Trinity Health Michigan d/b/a Trinity Health Grand Rapids Hospital
Grand Rapids, Michigan
ID Care
Hillsborough, New Jersey
Saint Michael's Medical Center
Newark, New Jersey
AXCES Research Group, LLC
Santa Fe, New Mexico
NewYork-Presbyterian Queens
Flushing, New York
Northwell Health/Division of Infectious Diseases
Manhasset, New York
Jacobi Medical Center
The Bronx, New York
Montefiore Medical Center
The Bronx, New York
Duke University Health System(DUHS)
Durham, North Carolina
ECU Health Leo Jenkins Cancer Building
Greenville, North Carolina
Rosedale Health and Wellness
Huntersville, North Carolina
University of Cincinnati College of Medicine
Cincinnati, Ohio
Prisma Health Midlands - Clinical Research Unit
Columbia, South Carolina
Showing 40 of 100 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.